Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glutathione disodium is a small molecule antioxidant drug consisting of the disodium salt of reduced glutathione (GSH). It is primarily investigated for its ability to scavenge reactive oxygen species (ROS), thereby reducing oxidative stress and preventing ischemia-reperfusion injury in patients undergoing primary percutaneous coronary intervention (PCI) for acute ST-elevation myocardial infarction (STEMI). The drug was evaluated in the Phase 2 GSH 2014 Trial, sponsored by University Hospital Policlinico Umberto I in Italy, where it was administered intravenously to protect cardiac and renal tissues. It is manufactured by Biomedica Foscama Group and remains an investigational compound in the context of acute myocardial infarction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glutathione disodium.